{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:33:49Z","timestamp":1791498829274,"version":"4.3.4"},"reference-count":64,"publisher":"Harborside Press, LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Transplantation, surgical resection, radiofrequency ablation, and percutaneous ethanol injection are generally considered potentially curative treatments for patients with hepatocellular carcinoma (HCC). With the increasing incidence of HCC, it is critical to investigate geographic variations in curative treatments and their associations with survival among patients. <jats:bold>Methods:<\/jats:bold> A total of 6,782 patients with HCC during 2004 to 2011 were identified in the SEER-Medicare linked database and placed in quartiles based on the proportions undergoing potentially curative treatments per hospital referral region (HRR). Hierarchical Cox proportional hazards models were used to examine the association between regional potentially curative treatment patterns and survival across quartiles. <jats:bold>Results:<\/jats:bold> An average of 16.9% of patients with HCC underwent potentially curative treatments during 2004 to 2011, varying substantially from 0% to 34.5% across HRRs. Compared with patients residing in the lowest-quartile regions, those in the highest-quartile regions were more likely to be of other races (vs white or black), be infected with hepatitis B virus, and have more comorbidities. The 5-year survival was 4.7% in the lowest-quartile regions and 11.4% in the highest-quartile regions (<jats:italic>P<\/jats:italic>&lt;.001). After controlling for confounders, patients in the highest-quartile regions had a lower risk of mortality (adjusted hazard ratio, 0.78; 95% CI, 0.72\u20130.85). <jats:bold>Conclusions:<\/jats:bold> Patients with HCC who resided in HRRs with higher proportions of potentially curative treatments had better survival. Given its proven survival benefits, prompt clinical and policy actions are needed to reduce variations in treatment utilization.<\/jats:p>","DOI":"10.6004\/jnccn.2020.7529","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T19:31:47Z","timestamp":1591385507000},"page":"729-736","source":"Crossref","is-referenced-by-count":5,"title":["Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study"],"prefix":"10.6004","volume":"18","author":[{"given":"En","family":"Cheng","sequence":"first","affiliation":[{"name":"1Department of Chronic Disease Epidemiology, School of Public Health, Yale University, New Haven, Connecticut;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyin","family":"Hung","sequence":"additional","affiliation":[{"name":"2Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, and"},{"name":"3Rural and Minority Health Research Center, Columbia, South Carolina; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Chronic Disease Epidemiology, School of Public Health, Yale University, New Haven, Connecticut;"},{"name":"4Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref321","doi-asserted-by":"crossref","first-page":"987","DOI":"10.6004\/jnccn.2015.0119","article-title":"Treatment patterns and outcomes in patients with hepatocellular carcinoma stratified by stage-guided treatment categories","volume":"13","author":"Kuo","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","article-title":"Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma","volume":"150","author":"Bruix","year":"2016","journal-title":"Gastroenterology"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s11605-007-0315-8","article-title":"Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma","volume":"11","author":"Sonnenday","year":"2007","journal-title":"J Gastrointest Surg"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s11605-007-0315-8","article-title":"Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma","volume":"11","author":"Sonnenday","year":"2007","journal-title":"J Gastrointest Surg"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/JCO.2000.18.5.1094","article-title":"Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis","volume":"18","author":"Poon","year":"2000","journal-title":"J Clin Oncol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.amepre.2018.05.030","article-title":"Racial and geographic disparities in hepatocellular carcinoma outcomes","volume":"55","author":"Franco","year":"2018","journal-title":"Am J Prev Med"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-2005-871198","article-title":"Resection and liver transplantation for hepatocellular carcinoma","volume":"25","author":"Llovet","year":"2005","journal-title":"Semin Liver Dis"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/hep.22648","article-title":"Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies","volume":"49","author":"Cho","year":"2009","journal-title":"Hepatology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000446382","article-title":"Organ transplantation in the face of donor shortage: ethical implications with a focus on liver allocation","volume":"32","author":"Lauerer","year":"2016","journal-title":"Visc Med"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000446382","article-title":"Organ transplantation in the face of donor shortage: ethical implications with a focus on liver allocation","volume":"32","author":"Lauerer","year":"2016","journal-title":"Visc Med"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"ref551","first-page":"511","article-title":"Hepatic resection for hepatocellular carcinoma","volume":"107","author":"Tsuzuki","year":"1990","journal-title":"Surgery"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"987","DOI":"10.6004\/jnccn.2015.0119","article-title":"Treatment patterns and outcomes in patients with hepatocellular carcinoma stratified by stage-guided treatment categories","volume":"13","author":"Kuo","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"ref181","first-page":"511","article-title":"Hepatic resection for hepatocellular carcinoma","volume":"107","author":"Tsuzuki","year":"1990","journal-title":"Surgery"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jhep.2005.10.002","article-title":"Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study","volume":"44","author":"El-Serag","year":"2006","journal-title":"J Hepatol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/cncr.31551","article-title":"Annual report to the nation on the status of cancer, part I: national cancer statistics","volume":"124","author":"Cronin","year":"2018","journal-title":"Cancer"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0002-9610(01)00844-3","article-title":"A 15-year retrospective study of hepatic resection for stage IV-A hepatocellular carcinoma shows value in hepatitis B negative patients","volume":"183","author":"Hanazaki","year":"2002","journal-title":"Am J Surg"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1023\/A:1008285123736","article-title":"Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials","volume":"8","author":"Simonetti","year":"1997","journal-title":"Ann Oncol"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2174\/1574887111999160701091605","article-title":"Hepatocellular carcinoma in alcoholic liver disease: current management and recent advances","volume":"11","author":"Galati","year":"2016","journal-title":"Rev Recent Clin Trials"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/01.SLA.0000055224.68432.80","article-title":"Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification","volume":"237","author":"Poon","year":"2003","journal-title":"Ann Surg"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/hep.22648","article-title":"Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies","volume":"49","author":"Cho","year":"2009","journal-title":"Hepatology"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jhep.2005.10.002","article-title":"Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study","volume":"44","author":"El-Serag","year":"2006","journal-title":"J Hepatol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000343828","article-title":"Treatment of hepatocellular carcinoma: a systematic review","volume":"1","author":"Lin","year":"2012","journal-title":"Liver Cancer"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"IV-3","DOI":"10.1097\/00005650-200208001-00002","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/ajg.2014.11","article-title":"Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States","volume":"109","author":"Altekruse","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3322\/caac.21402","article-title":"Disparities in liver cancer occurrence in the United States by race\/ethnicity and state","volume":"67","author":"Islami","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2016.11.020","article-title":"Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012","volume":"152","author":"White","year":"2017","journal-title":"Gastroenterology"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/ajg.2014.11","article-title":"Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States","volume":"109","author":"Altekruse","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0039-6060(96)80260-1","article-title":"Surgical treatment strategy for patients with stage IV hepatocellular carcinoma","volume":"119","author":"Shimada","year":"1996","journal-title":"Surgery"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.cgh.2015.12.044","article-title":"Effects of cirrhosis on short-term and long-term survival of patients with hepatitis B-related hepatocellular carcinoma","volume":"14","author":"Chen","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000343828","article-title":"Treatment of hepatocellular carcinoma: a systematic review","volume":"1","author":"Lin","year":"2012","journal-title":"Liver Cancer"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3322\/caac.21402","article-title":"Disparities in liver cancer occurrence in the United States by race\/ethnicity and state","volume":"67","author":"Islami","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-2005-871198","article-title":"Resection and liver transplantation for hepatocellular carcinoma","volume":"25","author":"Llovet","year":"2005","journal-title":"Semin Liver Dis"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1200\/JCO.2013.49.6489","article-title":"Marital status and survival in patients with cancer","volume":"31","author":"Aizer","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/cncr.28730","article-title":"The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review","volume":"120","author":"Fong","year":"2014","journal-title":"Cancer"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/cncr.28730","article-title":"The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review","volume":"120","author":"Fong","year":"2014","journal-title":"Cancer"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2174\/1574887111999160701091605","article-title":"Hepatocellular carcinoma in alcoholic liver disease: current management and recent advances","volume":"11","author":"Galati","year":"2016","journal-title":"Rev Recent Clin Trials"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"IV-3","DOI":"10.1097\/00005650-200208001-00002","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0002-9610(01)00844-3","article-title":"A 15-year retrospective study of hepatic resection for stage IV-A hepatocellular carcinoma shows value in hepatitis B negative patients","volume":"183","author":"Hanazaki","year":"2002","journal-title":"Am J Surg"},{"key":"ref371","first-page":"1975","article-title":"eds SEER National Institute Bethesda MD Available at https seer cancer gov csr based on November SEER data submission posted to the SEER web site Accessed","volume":"31","author":"NooneAM","year":"2017","journal-title":"Cancer Statistics Review Cancer"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.cgh.2015.12.044","article-title":"Effects of cirrhosis on short-term and long-term survival of patients with hepatitis B-related hepatocellular carcinoma","volume":"14","author":"Chen","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1097\/SLA.0b013e31827da749","article-title":"Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-Medicare analysis","volume":"258","author":"Nathan","year":"2013","journal-title":"Ann Surg"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/JCO.2000.18.5.1094","article-title":"Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis","volume":"18","author":"Poon","year":"2000","journal-title":"J Clin Oncol"},{"key":"ref01","first-page":"1975","article-title":"eds SEER National Institute Bethesda MD Available at https seer cancer gov csr based on November SEER data submission posted to the SEER web site Accessed","volume":"31","author":"NooneAM","year":"2017","journal-title":"Cancer Statistics Review Cancer"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archsurg.143.6.538","article-title":"Treatment of stage IVA hepatocellular carcinoma: should we reappraise the role of surgery?","volume":"143","author":"Chirica","year":"2008","journal-title":"Arch Surg"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/cncr.31551","article-title":"Annual report to the nation on the status of cancer, part I: national cancer statistics","volume":"124","author":"Cronin","year":"2018","journal-title":"Cancer"},{"key":"ref141","first-page":"179","article-title":"Thirty years of Medicare: impact on the covered population","volume":"18","author":"Gornick","year":"1996","journal-title":"Health Care Financ Rev"},{"key":"ref511","first-page":"179","article-title":"Thirty years of Medicare: impact on the covered population","volume":"18","author":"Gornick","year":"1996","journal-title":"Health Care Financ Rev"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1200\/JCO.2013.49.6489","article-title":"Marital status and survival in patients with cancer","volume":"31","author":"Aizer","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/01.SLA.0000055224.68432.80","article-title":"Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification","volume":"237","author":"Poon","year":"2003","journal-title":"Ann Surg"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","article-title":"Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma","volume":"150","author":"Bruix","year":"2016","journal-title":"Gastroenterology"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archsurg.143.6.538","article-title":"Treatment of stage IVA hepatocellular carcinoma: should we reappraise the role of surgery?","volume":"143","author":"Chirica","year":"2008","journal-title":"Arch Surg"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2016.11.020","article-title":"Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012","volume":"152","author":"White","year":"2017","journal-title":"Gastroenterology"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1097\/SLA.0b013e31827da749","article-title":"Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-Medicare analysis","volume":"258","author":"Nathan","year":"2013","journal-title":"Ann Surg"},{"key":"ref361","article-title":"for Medicare Medicaid Services Medicare Trustees Report Accessed Available at https www cms gov Research Statistics Data and Systems Statistics Trends and Reports ReportsTrustFunds Downloads pdf","author":"Centers","year":"2019","journal-title":"October"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"ref731","article-title":"for Medicare Medicaid Services Medicare Trustees Report Accessed Available at https www cms gov Research Statistics Data and Systems Statistics Trends and Reports ReportsTrustFunds Downloads pdf","author":"Centers","year":"2019","journal-title":"October"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1023\/A:1008285123736","article-title":"Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials","volume":"8","author":"Simonetti","year":"1997","journal-title":"Ann Oncol"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0039-6060(96)80260-1","article-title":"Surgical treatment strategy for patients with stage IV hepatocellular carcinoma","volume":"119","author":"Shimada","year":"1996","journal-title":"Surgery"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.amepre.2018.05.030","article-title":"Racial and geographic disparities in hepatocellular carcinoma outcomes","volume":"55","author":"Franco","year":"2018","journal-title":"Am J Prev Med"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/6\/article-p729.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/18\/6\/article-p729.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T18:58:13Z","timestamp":1592593093000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/6\/article-p729.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":64,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2020.7529","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}